FDA approves single REMS for transmucosal immediate-release fentanyl products

The U.S. Food and Drug Administration has approved a single shared Risk Evaluation and Mitigation Strategy (REMS) for transmucosal immediate-release fentanyl (TIRF) products. This new system will replace individual REMS and allow prescribers to enroll into just one system. Read more.

LEAVE A REPLY

Please enter your comment!
Please enter your name here